ArticleArchives of osteoporosis2025
Vertebral changes evaluated by hounsfield units after spinal fusion surgery with concomitant anabolic therapy.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of Perioperative Teriparatide Use with Postoperative Complications in Spinal Fusion Surgery: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analyzed vertebral changes in spinal fusion patients treated with teriparatide or romosozumab. Both therapies improved bone quality, but romosozumab showed a significantly greater HU increase. These findings suggest that romosozumab demonstrated a more pronounced effect than TPD in patients undergoing spinal fusion surgery. PURPOSE: Osteoporosis negatively impacts spinal fusion surgery outcomes. Although teriparatide (TPD) has been used perioperatively, romosozumab (ROMO) has recently gained attention. This study aimed to evaluate changes in vertebral bone density using computed tomography (CT)-derived Hounsfield units (HU) before and after spinal fusion surgery and to examine the impact of concomitant bone anabolic therapy.
methodsThis is retrospective cohort study included 115 patients who underwent spinal fusion surgery between 2021 and 2023. Patients were categorized into three groups: non-osteoporosis, teriparatide-treated, and romosozumab-treated (n = 27, each). Osteoporosis therapy was initiated 59.5 days preoperatively and continued postoperatively. HU values were assessed at the levels of one and two vertebrae above the uppermost instrumented level (HU + 1, HU + 2) at two time points: preoperatively and 12 months postoperatively. The primary outcome measure was the percent change of HU values over time.
resultsThe non-osteoporosis group exhibited no significant changes in HU values 12 months postoperatively. Both the TPD and ROMO groups demonstrated significant increases in the percent change of HU values from baseline to 12 months postoperatively. Moreover, the ROMO group exhibited a significantly greater increase in the percent change of HU values than the non-osteoporosis and TPD groups at HU + 1. (p < 0.001 and p < 0.009, respectively).
conclusionPerioperative administration of TPD and ROMO significantly improved vertebral bone density, as determined by HU values. ROMO demonstrated a more pronounced effect than TPD, suggesting that it may be the preferred option for optimizing bone density in patients undergoing spinal fusion surgery.
Indexed as
Identifiers
41364149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.